Returns
| Series | 1 week | 1 month | 3 months | 6 months | YTD | 1 year | 3 years (ann.) | 5 years (ann.) | 10 years (ann.) | Since inception (ann.) |
|---|---|---|---|---|---|---|---|---|---|---|
| Market-price return | -2.39% | -13.70% | -13.96% | -3.44% | +2.15% | +5.74% | +11.74% | -3.73% | -0.06% | +1.23% |
| Market-price total return | -2.39% | -13.70% | -11.48% | +2.57% | +12.12% | +19.52% | +26.63% | +7.61% | +10.22% | +10.84% |
| NAV return | -4.90% | -15.03% | -19.84% | -9.57% | -3.67% | -2.14% | +5.94% | -2.99% | -0.36% | +2.47% |
| NAV total return | -4.90% | -15.03% | -17.64% | -4.38% | +4.95% | +9.40% | +18.47% | +7.23% | +9.02% | +12.02% |
Performance through Oct 14, 2026. Price and NAV returns are simple changes; total returns reinvest each distribution at the series value on its ex-date (first observation on/after). Periods of one year or less are cumulative; longer periods are annualised. Series are built from unadjusted prices plus the distribution record so no distribution is counted twice. Corporate actions: the vendor price series is split-adjusted; rights offerings and mergers are not restated — check Corporate Actions.
Growth of $10,000, five years
Risk statistics
| Statistic | Market price | NAV | Specification |
|---|---|---|---|
| Volatility, 1 year | 0.24% | 0.33% | annualised SD of daily total returns, √252 |
| Volatility, 3 years | 0.21% | 0.25% | as above |
| Volatility, 5 years | 0.21% | 0.23% | as above |
| Maximum drawdown, 3 years | -25.11% | -24.67% | peak-to-trough on the total-return index |
| Sharpe ratio, 3 years | 1.01 | 0.66 | excess over FRED DGS3MO (window average) (avg 4.52%), annualised |
| Sortino ratio, 3 years | 1.47 | 0.94 | downside deviation of excess returns |
| Beta vs. benchmark proxy, 3 years | 0.72 | — | SPY (U.S. equity ETF proxy), daily, aligned dates |
| Correlation, 3 years | 0.51 | — | as above |
| Observations (3y) | 751 | — | minimum 60; rankings require 500 |
Market-price and NAV volatility are different quantities and are never mixed. NAV volatility for funds holding stale-marked or illiquid assets can understate economic risk.
CEF Explorer research page for abrdn Life Sciences Investors. Figures carry their own dates and sources; a discount to NAV does not guarantee convergence or any return. This is not investment advice.